These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 20132966)

  • 1. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
    Raynauld JP; Martel-Pelletier J; Beaulieu A; Bessette L; Morin F; Choquette D; Haraoui B; Abram F; Pelletier JP
    Semin Arthritis Rheum; 2010 Dec; 40(3):185-92. PubMed ID: 20132966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
    Mastbergen SC; Marijnissen AC; Vianen ME; Zoer B; van Roermund PM; Bijlsma JW; Lafeber FP
    Rheumatology (Oxford); 2006 Apr; 45(4):405-13. PubMed ID: 16287921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
    Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis.
    Pelletier JP; Raynauld JP; Caron J; Mineau F; Abram F; Dorais M; Haraoui B; Choquette D; Martel-Pelletier J
    Ann Rheum Dis; 2010 Dec; 69(12):2095-101. PubMed ID: 20570834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.
    Moreno-Rubio J; Herrero-Beaumont G; Tardio L; Alvarez-Soria MA; Largo R
    Arthritis Rheum; 2010 Feb; 62(2):478-88. PubMed ID: 20112374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
    Wildi LM; Raynauld JP; Martel-Pelletier J; Abram F; Dorais M; Pelletier JP
    Ann Rheum Dis; 2010 Dec; 69(12):2118-24. PubMed ID: 20610445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.
    de Boer TN; Huisman AM; Polak AA; Niehoff AG; van Rinsum AC; Saris D; Bijlsma JW; Lafeber FJ; Mastbergen SC
    Osteoarthritis Cartilage; 2009 Apr; 17(4):482-8. PubMed ID: 18926729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.
    Raynauld JP; Martel-Pelletier J; Berthiaume MJ; Abram F; Choquette D; Haraoui B; Beary JF; Cline GA; Meyer JM; Pelletier JP
    Ann Rheum Dis; 2008 May; 67(5):683-8. PubMed ID: 17728333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study.
    Roy V; Gupta U; Sharma S; Dhaon BK; Singh NP; Gulati P
    J Indian Med Assoc; 1999 Oct; 97(10):442-5. PubMed ID: 10638109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties.
    Panahifar A; Jaremko JL; Tessier AG; Lambert RG; Maksymowych WP; Fallone BG; Doschak MR
    Osteoarthritis Cartilage; 2014 Oct; 22(10):1639-50. PubMed ID: 25278073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
    Clegg DO; Reda DJ; Harris CL; Klein MA; O'Dell JR; Hooper MM; Bradley JD; Bingham CO; Weisman MH; Jackson CG; Lane NE; Cush JJ; Moreland LW; Schumacher HR; Oddis CV; Wolfe F; Molitor JA; Yocum DE; Schnitzer TJ; Furst DE; Sawitzke AD; Shi H; Brandt KD; Moskowitz RW; Williams HJ
    N Engl J Med; 2006 Feb; 354(8):795-808. PubMed ID: 16495392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population.
    Nadarajah A; Abrahan L; Lau FL; Hwang LJ; Fakir-Bolte C
    Singapore Med J; 2006 Jun; 47(6):534-42. PubMed ID: 16752024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674
    [No Abstract]   [Full Text] [Related]  

  • 20. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.